CoreMap, Inc. — SEC Form D Filing
CoreMap, Inc. filed an SEC Form D on June 24, 2026, reporting $35.51M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 24, 2026
- Amount reported
- $35.51M
- Industry
- Medical Devices
- Website
- https://coremapmedical.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Atrial fibrillation (AF) is an irregular heartbeat that can cause blood clots, stroke, and heart failure, affecting millions of patients. Current treatments for permanent and persistent AF are not universally effective for all patients.
Solution
CoreMap is developing advanced diagnostic technology, specifically ultra-high resolution electrodes, to allow physicians to visualize atrial fibrillation and enable patient-specific treatments for complex atrial arrhythmias.
Verdict
Investors backed this round because the technology offered a credible path to more effective treatment for a large, well-understood clinical problem, not because of a disruptive payment model. They were implicitly betting on a regulatory pathway that would validate the device's diagnostic superiority and translate directly into improved patient outcomes, justifying its premium. The upside was limited by the incremental nature of diagnostic improvement within an established treatment paradigm, rather than fundamentally changing how care is delivered.
Source: SEC EDGAR Form D filing